Why is this medication prescribed?

Retifanlimab, or retifanlimab-dlwr, is prescribed for the treatment of a specific type of cancer called advanced or metastatic squamous cell carcinoma of the anal canal (SCAC). Squamous cell carcinoma is a type of cancer that originates from squamous cells, which are flat cells found in various tissues of the body.

Retifanlimab is a monoclonal antibody that targets the PD-1 receptor. PD-1 is a protein on the surface of certain immune cells that helps regulate the immune response. By blocking the PD-1 pathway, retifanlimab enhances the body’s immune system’s ability to recognize and attack cancer cells.

How should this medicine be used?

Typically, Retifanlimab-dlwr is administered as an intravenous (IV) infusion. The infusion is usually given over a specified period, and the dosage and frequency depend on factors such as the type of cancer being treated and the patient’s overall health. The treatment plan and dosage are determined by the prescribing healthcare provider.

Here are general steps for the administration of an intravenous infusion, but please note that these are general guidelines and may not specifically apply to Retifanlimab-dlwr:

• Preparation: The healthcare provider will prepare the drug according to the prescribing information, considering factors such as the patient’s weight and the recommended dosage.
• Intravenous Access: The medication is typically administered through a vein, often in the arm.
• Infusion: The drug is infused over a specific period, and the patient is monitored during and after the infusion for any potential adverse reactions.
• Follow-up: After the infusion, patients may have follow-up appointments to monitor their response to the treatment and manage any side effects.

It is crucial for patients to follow the healthcare provider’s instructions regarding the administration of Retifanlimab-dlwr and to attend all scheduled appointments. Additionally, patients should communicate any concerns or potential side effects to their healthcare team promptly.

For the most accurate and up-to-date information on how Retifanlimab-dlwr should be used, please consult the prescribing information provided by the drug manufacturer or consult directly with a healthcare professional.

Other uses for this medicine

As of last update, retifanlimab was primarily indicated for the treatment of advanced or metastatic squamous cell carcinoma of the anal canal. However, ongoing research and clinical trials may explore its potential use in other cancer types or conditions.

What special precautions should I follow?

As of last update, some general precautions that might apply to immunotherapy drugs, including PD-1 inhibitors like Retifanlimab-dlwr, include:

• Immune-related Adverse Events (irAEs): These drugs can lead to immune-related side effects that may affect various organs. It’s important for patients to report any new or worsening symptoms promptly.
• Infections: Patients may have an increased risk of infections. Monitoring for signs of infection and seeking prompt medical attention for any signs of illness is essential.
• Pregnancy and Breastfeeding: The potential risks to a developing fetus or a nursing infant should be considered. Patients should discuss their pregnancy or breastfeeding status with their healthcare provider.
• Pre-existing Medical Conditions: Patients with pre-existing autoimmune conditions or a history of organ transplantation may have an increased risk of immune-related adverse reactions.
• Monitoring: Regular monitoring, including laboratory tests and imaging studies, may be required to assess treatment response and detect any potential side effects.

It’s important to remember that individual patient circumstances can vary, and healthcare providers will tailor their recommendations based on the specific clinical situation. Patients should openly communicate with their healthcare team about their medical history, any ongoing medications, and any concerns or questions they may have about Retifanlimab-dlwr.

For the most current and specific information regarding Retifanlimab-dlwr, consult the prescribing information provided by the drug manufacturer or seek guidance from a healthcare professional.

What special dietary instructions should I follow?

As of last update, there were no specific dietary restrictions associated with Retifanlimab-dlwr. However, dietary considerations can vary based on individual health conditions and may be subject to change. Always consult with your healthcare provider for personalized advice.

What should I do if I forget a dose?

Since Retifanlimab-dlwr is typically administered by a healthcare professional as an intravenous infusion, it’s unlikely for a patient to forget a dose. The schedule for treatment is usually determined by the healthcare provider, and missing a dose can impact the effectiveness of the treatment.

What side effects can this medication cause?

Retifanlimab-dlwr, like other immunotherapy drugs, may cause a range of side effects. It’s important to note that individual responses to the medication can vary, and not everyone will experience the same side effects. Additionally, the severity of side effects can differ from person to person. The following list includes some potential side effects associated with Retifanlimab-dlwr as of last update:

• Immune-Related Adverse Events (irAEs): These can affect various organs and systems in the body. Common irAEs include rash, diarrhea, colitis, hepatitis, and pneumonitis.
• Fatigue: Feeling tired or having low energy levels is a common side effect.
• Skin Reactions: Skin-related side effects may include rash, itching, and changes in skin color.
• Gastrointestinal Issues: Diarrhea, nausea, vomiting, and abdominal pain may occur.
• Endocrine Disorders: Disruption of hormone levels can lead to thyroid disorders or adrenal insufficiency.
• Respiratory Issues: Cough, shortness of breath, and other respiratory symptoms may occur.
• Infusion Reactions: Some individuals may experience reactions during or after the infusion, such as fever, chills, or difficulty breathing.
• Infections: Immunotherapy can weaken the immune system, potentially increasing the risk of infections.
• Musculoskeletal Issues: Joint pain and muscle pain are possible side effects.
• Liver Dysfunction: Changes in liver function may occur, leading to elevated liver enzymes.

It’s crucial to report any side effects promptly to your healthcare provider. Some side effects may require medical attention, and your healthcare team will assess the severity and provide appropriate management.

This is not an exhaustive list, and other side effects may occur. Always refer to the most recent prescribing information for Retifanlimab-dlwr or consult with a healthcare professional for the latest and most accurate information based on your specific situation.

What should I know about storage and disposal of this medication?

Storage and Disposal:

• Storage: Follow the storage recommendations provided by your healthcare provider or pharmacist. Medications like Retifanlimab-dlwr are typically stored in a controlled environment, and it’s important to adhere to specific temperature and storage guidelines.
• Disposal: Proper disposal of unused or expired medications is crucial for safety and environmental reasons. Your healthcare provider or pharmacist can provide guidance on the appropriate disposal method for Retifanlimab-dlwr. Do not dispose of medications in household trash or wastewater without proper instructions.

In case of emergency/overdose

In case of emergency or suspected overdose, it’s important to seek immediate medical attention. Contact your local poison control center or emergency room for guidance. Provide as much information as possible, including the name of the medication (Retifanlimab-dlwr), the amount taken, and the time of ingestion.

What other information should I know?

• Follow-up Appointments: Attend all scheduled appointments with your healthcare provider. Regular check-ups are essential to monitor your response to treatment and manage any potential side effects.
• Communication: Inform your healthcare team about any new or worsening symptoms, changes in health, or concerns you may have during treatment.
• Pregnancy and Breastfeeding: If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your healthcare provider. The potential risks and benefits of continuing treatment during pregnancy or while breastfeeding should be considered.
• Other Medications and Supplements: Inform your healthcare provider about all medications, including prescription and over-the-counter drugs, as well as any supplements you are taking. Some medications and supplements may interact with Retifanlimab-dlwr.

Always consult your healthcare provider or pharmacist for the most current and specific information related to Retifanlimab-dlwr. They can provide personalized guidance based on your medical history and individual circumstances.